M&A Deal Summary

Roche Acquires Telavant

On October 23, 2023, Roche acquired life science company Telavant from Roivant Sciences for 7.1B USD

Acquisition Highlights
  • This is Roche’s 28th transaction in the Life Science sector.
  • This is Roche’s 3rd largest (disclosed) transaction.
  • This is Roche’s 27th transaction in the United States.
  • This is Roche’s 1st transaction in New York.

M&A Deal Summary
Date 2023-10-23
Target Telavant
Sector Life Science
Buyer(s) Roche
Sellers(s) Roivant Sciences
Deal Type Divestiture
Deal Value 7.1B USD

Target

Telavant

New York, New York, United States
Telavant is the developer of RVT-3101, a novel TL1A directed antibody. RVT-3101 is a therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Telavant is based in New York, New York.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 60.4B CHF (2023)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 41 of 42
Sector (Life Science) 28 of 29
Type (Divestiture) 3 of 3
State (New York) 1 of 1
Country (United States) 27 of 28
Year (2023) 1 of 2
Size (of disclosed) 3 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-09-07 Good Therapeutics

Seattle, Washington, United States

Good Therapeutics is a biopharmaceutical company focused on the generation of a new class of drugs that offer potent activity only where it is needed. The therapeutic component can be regulated by any molecule that an antibody can bind, including native proteins, modified proteins, and metabolites. Good Therapeutics’ technology is applicable to a wide range of areas including cancer, autoimmune diseases, metabolic disease, and pain management. Good Therapeutics was founded in 2016 and is based in Seattle, Washington.

Buy $250M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-04 Carmot

Berkeley, California, United States

Carmot is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes. The company's expertise in metabolic biology has enabled the development of a broad pipeline of therapeutics, including three clinical candidates: CT-388 (once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist), CT-996 (once-daily oral, small molecule GLP-1 receptor agonist) and CT-868 (once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist) and other molecules in preclinical development. Carmot is based in Berkeley, California.

Buy $2.7B

Seller(S) 1

SELLER

Roivant Sciences

London, United Kingdom
Category Company
Founded 2014
Sector Life Science
Employees908
Revenue 125M USD (2024)
DESCRIPTION

Roivant Sciences develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies. Roivant Sciences was founded in 2014 and is based in London, United Kingdom.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 2
Year (2023) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-02-26 Silicon Therapeutics

Boston, Massachusetts, United States

Silicon Therapeutics LLC is a fully integrated drug design and development company focused on small molecule therapeutics. The Silicon Therapeutics proprietary physics-driven drug design platform combines quantum physics, statistical thermodynamics, molecular simulations, a dedicated HPC super-computing cluster, purpose-built software, in-house laboratories and clinical development capabilities. Silicon Therapeutics is based in Boston, Massachusetts.

Buy $450M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-09-18 Dermavant Sciences

Long Beach, California, United States

Dermavant Sciences is focused on developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant Science’s medical dermatology pipeline includes earlier-development, late-stage, and commercialized, product candidates that target specific unmet needs in growing immuno-dermatology markets, plaque psoriasis and atopic dermatitis, as well as other immunological and inflammatory diseases. Dermavant Sciences was founded in 2015 and is based in Long Beach, California.

Sell $1.2B
Mergr

Product

Company

Legal